Arkolith/Insider Trading/CCCC/Form 4

Hirsch Andrew

President & CEO, DirectorC4 Therapeutics, Inc. (CCCC) · full profile →Form 4 · filed Feb 18, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 15, 2025Tax withholding(F)9K$3.18$30K423K
Feb 14, 2025Grant(A)224K—$0445K
Feb 14, 2025Tax withholding(F)13K$3.18$41K433K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 14, 2025Grant(A)335K—$0335K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001662579-25-000021) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML